EATRIS Combined Platform Meeting

Date & Time December 11 - 12, 2018
Address Miklošičeva ulica 1, 1000 Ljubljana, Slovenia
Location Grand Union Hotel, Ljubljana, Slovenia

The 2018 EATRIS Combined Platform Meeting will be held in Ljubljana on December 11 and 12. Like in previous years, the Platform Combined Meeting will be the moment to discuss the EATRIS platform activities and future strategies together, providing formidable networking opportunities. We would very much welcome your contribution as a guest speaker at one of our break-out sessions as well as for posters. To submit your abstract, please follow this link until October 14.

This year the Platform Combined Meeting will also be followed by a two-day CORBEL open workshop on the theme of public-private collaboration. This 2-day event on December 12 and 13, 2018 (back to back with the Combined EATRIS Platform meeting in Ljubljana) will focus on all relevant aspects of setting up such collaborations, from initial contacts through planning and negotiation to completion of legal agreements and project implementation.

With regards to accommodation, we have reserved a block of rooms at the Grand Union Hotel at a discounted rate starting from 115€ per night. Reserve now your Business room (115€) or your Comfort room (135€).

Travel and accommodation reimbursement can be submitted after the meeting, up to 250€ for one person per platform per institution. The fund is limited and each submission is subject to review prior proceeding. To submit your reimbursement, please contact before January 18 2019.



Tuesday December 11

09.30 – 10.30 Plenary session

– General opening – Irena Mlinaric and Dr. Jernej Stromajer, States Secretary from the Ministry of Education, Science and Sport
– EATRIS overview and update on activities – Anton Ussi
– EATRIS scientific community: present and future – Toni Andreu
– Keynote lecture – Tim Hubbard, Genomics England, London, UK

12.30 – 13.30 Lunch

13.30 – 17.30 Break-out sessions

– A Multimodal approaches connecting Atoms to Anatomy*

 B Multimodal approaches for immunomodulation and immunomonitoring**

 C Multimodal approaches for patient stratification***

17.30 – 19.00 Poster session and networking drinks

19.30         Dinner


Wednesday December 12

09.30 – 10.45 Plenary session

Feedback from the break-out sessions

10.45 – 11.15          Coffee break and open discussion

11.15 – 12.00 Plenary session

– Strategy/positioning for an EU RI
– Platforms
– Operations

12.00 – 13.00 Lunch

13.00 – 13.45 Plenary session

– Strategy with national nodes – Anton Ussi

13.45 – 14.00 Closure

14.00 – 16.00 Strategy meeting (EATRIS National Directors and Platform Chairs only)


*Multimodal approaches connecting Atoms to Anatomy

An integrated understanding of mechanisms underlying disease phenomena can create new opportunities for therapeutic development. The modern translational research toolbox is maturing with multi-modal technologies that allow deep investigation of integrated biological systems and pathways rather than looking at isolated targets. For example, early clinical trials using whole body (multimodal) and functional imaging can provide key insights for target engagement, PK/PD or dosing to help predicting R&D success at early stage. In silico analysis, machine learning and artificial intelligence approaches may lead to new insights and hypotheses that can ultimately result in novel molecular tools and drug candidates. This session will cover emerging theranostic approaches where a deep molecular understanding of target modulation is combined with a novel systemic therapeutic strategy.

Through sharing case studies, we intend to define for EATRIS:

– What is the current state of the art of theranostic approaches, within EATRIS and beyond

– What are key determinants for the predictive value of a specific approach

– How to achieve the highest translational potential for successful molecular intervention

13.30 – 14.05

Keynote – Evolution of multimodal imaging in translational oncology systems and their applications in therapeutics development

Prof. Emmet Mc Cormack , Professor Pharmaceutics & Pharmaceutical Technology, University of Bergen, Norway

14.05 – 14.40

Case study – A theranostic bench-to-bedside approach using sonoporation

Dr. Spiros Kotopoulis, Researcher, Dept Clinical Medicine, University of Bergen, Norway

14.40 – 15.15

Abstract – The SYNERGY project as an example of collaborative effort based on multimodal approaches for drug repurposing and personalized medicine in cancer

Dr. Maddalena Fratelli, Group leader, Dpt. Molecular Biochemistry and Pharmacology, Mario Negri Institute, Milan, Italy

15.15 – 15.45  Coffee break

15.45 – 16.20

Keynote – Overview of approaches using multimodal theranostic approaches involving MRI

Dr. Sébastien Mériaux on behalf of Prof. Cyril Poupon, Chief of MRI and Spectroscopy Laboratory, NeuroSpin, Co-Chair EATRIS Imaging & Tracing Platform, CEA, France

Co-Chair EATRIS Imaging & Tracing Platform

16.20 – 16.55

Case study – Translational research in molecular imaging using combined ultra-high field MRI and focused Ultrasound

Dr. Sébastien Mériaux, Team leader Molecular Imaging and Delivery of Active Substances, NeuroSpin, CEA, France

16.55 – 17.30

Abstract – Disease maps platform as a tool for data-driven visual analytics for understanding complex disease mechanisms

Dr. David Hoksza, Research Associate, Centre for Systems Biomedicine, University of Luxembourg, Luxembourg and Charles University, Prague

17.30 – 17.35


**Multimodal approaches for Immunomodulation and Immunomonitoring

 Description: Immune Cell therapy represents a revolutionary treatment for hematological malignancies evidenced by the recent breakthrough successes involving CAR-T therapies for B-Cell Leukemias. The success of this type of treatment, however, has not yet been realized in solid tumors. One hypothesis is that the immunosuppressive nature of the tumor microenvironment (TME) influences and affects the efficacy of adoptive immunotherapy. Understanding the role of the TME and its interaction with immune cell therapies is key to improve the potency of adoptive immunotherapy. These include identifying multimodal approaches to monitoring the limited trafficking of adoptively transferred cells to tumor sites, the identification of proper tumor-associated antigen and a greater understanding of the immunosuppressive effect of the tumor microenvironment. This session will discuss innovative multimodal approaches to immunomodulation and immunomonitoring to ensure the safest and most effective combinations of therapeutic modalities for patients with solid tumors.

13.30 – 14.00

Keynote – Beyond the stillness

Dr. Eduardo Lopez Collazo, Scientific Director, IDIPAZ, Madrid, Spain

14.00 – 14.30

Multimodal imaging for clinical immunotherapy

Dr. Mangala Srinivas, Assistant Professor, RadboudUMC, Nijmegen, The Netherlands; and GE Healthcare

14.30 – 15.00

“Non-invasive imaging of immune cells”

Dr. Bert Windhorst, Professor, VUMC, Amsterdam, The Netherlands, Co-Chair EATRIS Imaging & Tracing Platform

15.00 – 15.30 Open discussion

15.30 – 16.00 Coffee break

16.00- 16.20

Immunomonitoring at the crossroads of immunomodulation in cancer therapy

Dr. Lucia Gabriele, Researcher, Group Leader, ISS, Rome, Italy, Co-Chair EATRIS Vaccine Platform

16.20 – 16.40

Abstract – Targeting immune cells in colorectal cancer: new immunomodulators in metastasis

Dr. Luis Aguirre, Research Scientist, IDIPAZ, Madrid, Spain


16.40 – 17.30

Open discussion / Session deliverables

***Multimodal approaches for patient stratification

Description: Development of biomarkers for patient stratification is a vital concept to facilitate the development and implementation of personalized medicines. Multimodal biomarker approaches integrating various technologies (omics, imaging, functional readouts) are key in the development of high quality stratification biomarkers to enable personalized medicine diagnosis, prognosis and prediction of treatment effectiveness. The session will highlight the current achievements and challenges in patient stratification biomarker R&D. Through sharing examples, we intend to define our best practice within EATRIS on the following key issues:

– Technology push vs clinical pull

– Approaches to combine multi-omics approaches

– Quality, harmonization, standardization & reproducibility

– Follow-up translation to product

13.30 – 13.50

Introduction – X-omics approaches for patient stratification

Prof. Alain van Gool, Head Translational Metabolic Laboratory, RadboudUMC, Nijmegen, The Netherlands, Chair EATRIS Biomarker Platform

13.50 – 14.30

Challenges around omics implementation for patient stratification

Toni Andreu, MD, PhD, Scientific Director, EATRIS

Christiaan Vis, Associate researcher, Vrije Universiteit, Amsterdam, The Netherlands

14.30 – 14.55

Multi-modal data management, experience from the Translational Research IT (TraIT) initiative

Jan Willem Boiten, PhD, Programme Manager, Lygature, Utrecht, The Netherlands

14.55 – 15.20

Biomarkers for Adaptive Platform Trials

Fatima Nunez, PhD, Deputy Director, Vall d’Hebron Institute of Research (VHIR), Barcelona, Spain

15.20 – 15.40 Coffee break

15.40 – 16.00

Abstract 1 – Outcome prediction of metastatic colorectal cancer patients undergoing liver resection by analyzing serum metabolomics and cytokinomics as well as tumor tissue gene expression immunoprofiling

Alfredo Budillon, MD, PhD, Professor, Istituto Nazionale Tumori “Fondazione Pascale”, Naples, Italy, Co-Chair EATRIS Small Molecules Platform

16.00 – 16.20

Abstract 2 – Molecular Biomarkers for Personalised Biological therapy in chronic immune diseases using multi-omics approach

Prof. Uroš Potočnik, Professor, University of Maribor, Maribor, Slovenia

16.20 – 16.40

Abstract 3 – miRNAs are useful biomarkers for prognosis in pancreas cancer

Laura Bermejo, PhD, Vice Director at IRYCIS, Madrid, Spain

16.40 – 17.10 Discussion

Website by Lewis+Humphreys